BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of “Moderate Buy” by Analysts

BioNTech SE (NASDAQ:BNTX) has been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $109.09.

A number of equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft raised BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a report on Wednesday, August 7th. BMO Capital Markets dropped their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $113.00 target price on shares of BioNTech in a report on Monday, August 19th. Evercore ISI assumed coverage on shares of BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. Finally, HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BNTX. CWM LLC grew its holdings in BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after buying an additional 217 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares during the last quarter. Frazier Financial Advisors LLC purchased a new stake in BioNTech during the 4th quarter worth about $30,000. First Horizon Advisors Inc. acquired a new position in BioNTech in the 4th quarter valued at about $38,000. Finally, Covestor Ltd lifted its holdings in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Trading Up 1.1 %

Shares of BNTX stock opened at $88.19 on Monday. The company has a market capitalization of $20.97 billion, a P/E ratio of 176.28 and a beta of 0.23. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $83.96 and its two-hundred day moving average is $89.61. BioNTech has a twelve month low of $76.53 and a twelve month high of $125.83.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The business’s quarterly revenue was down 23.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.86) earnings per share. Equities analysts forecast that BioNTech will post -2.04 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.